ArticleMolecular psychiatry2026
The HDAC inhibitor sodium butyrate moderately enhances long-term fear extinction memory retrieval in humans.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Fear extinction and its persistence depend on epigenetic modifications, which can be potentiated by histone deacetylase inhibitors (HDACis). Butyrate (NaBu), a short-chain fatty acid and endogenous HDACi, promotes persistent fear extinction in rodent models by increasing histone acetylation in promoter regions of plasticity- and memory-related genes, thereby enhancing their transcription. To test translational relevance in humans, we conducted a six-arm randomized, triple-blind, placebo-controlled intervention study in 180 healthy participants who underwent a 3-day Pavlovian fear conditioning paradigm. Participants ingested a single dose of NaBu or placebo either before or after extinction learning, the duration of which was additionally manipulated by varying the number of learning trials. NaBu facilitated later retrieval of extinction memory after seven days, both when administered before or after extinction learning, but it did not prevent return of fear during a subsequent reinstatement test. Interestingly, NaBu's effects were contingent on robust extinction learning, emerging only when participants had been exposed to a high number of trials. As no side effects were observed with acute administration of the current dose, these findings support investigating NaBu as a potential adjunct for enhancing extinction-based interventions, such as prolonged exposure therapy, in anxiety disorders.
Identifiers
42557391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.